Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TDM of piperacillin in febrile neutropenia after chemotherapy
DRKS00011023Phase 4Terminated
- Sponsor
- Universitätsklinikum Jena
- Start
- Sep 2016
- Modality
- Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of piperacillin + tazobactam in febrile neutropenia (FN) and Infectious disease (2 arms), sponsored by Universitätsklinikum Jena. Primary endpoint: Pharmacokinetic target attainment of piperacillin. Started Sep 2016; status: terminated.
02
Drugs
piperacillin + tazobactam
03
Conditions
febrile neutropenia (FN)Infectious disease
Beyond the preview
Go deeper on DRKS00011023.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on DRKS00011023.